We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Asthma, Inflammation and G Protein-coupled Receptors (GPCR)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00793676
First Posted: November 19, 2008
Last Update Posted: September 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Research Agency, France
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
November 17, 2008
November 19, 2008
September 11, 2017
September 2008
September 2017   (Final data collection date for primary outcome measure)
differential expression of GPCRs [ Time Frame: 1 day ]
differencial expression of GPCRs [ Time Frame: 1 day ]
Complete list of historical versions of study NCT00793676 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
G Protein Coupled Receptor (GPCR)Signature as Biomarker of Chronic Pulmonary Inflammatory Diseases and of Therapeutic Follow-up
The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether GPCR expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.To do so , the investigators will determine the expression profile of the 380 human GPCRs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and COPD (chronic obstructive pulmonary disease ) . These have opposed inflammatory infiltrates : asthma is associated with eosinophil and Th2 lymphocyte infiltration whereas COPD shows neutrophils and macrophages within the airways with a Th1 lymphocytic population. The GPCR signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or COPD consultation. The expression profiling analysis will reveal sub-groups of GPCRs whose expression is modified in disease. The specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. The outcomes of the project will lead to establish GPCR "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. In addition, detailed analysis of the identified GPCRs will lead to propose new therapeutic targets for inflammatory diseases. This study has therefore the objective of validating GPCRs as potential biomarkers for inflammatory diseases.
Multicentre non-randomized
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
  • Asthma
  • COPD
  • Other: spirometry
  • Other: blood test
  • A= Asthma
    Interventions:
    • Other: spirometry
    • Other: blood test
  • B= COPD
    Intervention: Other: blood test
  • C= Control
    Intervention: Other: blood test
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
205
September 2017
September 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Asthma group
  • COPD group
  • Control group

Exclusion Criteria:

  • Patients with infection or inflammatory diseases
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00793676
4171
No
Not Provided
Not Provided
University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
National Research Agency, France
Principal Investigator: Romain Kessler, MD University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP